CN100394930C - Application of cassia seed in preparation of lead-remove promoting drug or health-caring product - Google Patents
Application of cassia seed in preparation of lead-remove promoting drug or health-caring product Download PDFInfo
- Publication number
- CN100394930C CN100394930C CNB2005101003474A CN200510100347A CN100394930C CN 100394930 C CN100394930 C CN 100394930C CN B2005101003474 A CNB2005101003474 A CN B2005101003474A CN 200510100347 A CN200510100347 A CN 200510100347A CN 100394930 C CN100394930 C CN 100394930C
- Authority
- CN
- China
- Prior art keywords
- lead
- semen cassiae
- group
- blood
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses the novel uses of cassia seed in preparing medicament for the promotion of lead discharging. Because cassia seed can be utilized as both medicinal and edible raw materials, and the cassia seed can be prepared into medicinal preparations or health-care products for people with high plumbum.
Description
Technical field
The present invention relates to a kind of raw material Semen Cassiae of medicine-food two-purpose, is the medicine of lead-eliminating effect in preparation promotes body or the purposes of health product specifically.
Technical background
Lead is a kind of human body non-essential element, and it is prevalent in natural atmosphere, soil, water and the food, can not decompose, and easily is absorbed by the body by digestive tract, respiratory tract.Its is put aside in each tissue of human body, and is wherein maximum with the skeleton amount of savings, accounts for and puts aside 85%～90% of lead in the body.
Plumbous affinity to tissue is very strong, can cause multiple organ injury diseases such as liver, brain, with nervous system injury more so, often causes diseases such as peripheral neuritis, motion and paraesthesia.If lead enters cerebral tissue with blood flow, can damage cerebellum and brain cortex cell, disturb metabolic activity, cause nutrient substance and oxygen supply deficiency, thereby symptoms such as headache, hypomnesis, insomnia appear, also often with gastrointestinal symptoms such as inappetence, gastroenteritis, stomachache.
Plumbous particularly serious to the harm of children's health and intellectual development, the energy force rate adult that the child resists the lead poisoning evil is poor; Child's living habit etc. causes the lead ratio adult who takes in by digestive tract and respiratory tract many; The lead that the adult takes in has 94% savings in sclerotin, the child then has only 70%, all the other 30% are stayed in the blood, child's blood brain barrier is grown imperfection, and permeability is big, and blood lead is easy to see through blood brain barrier brain is produced murder by poisoning, as untimely removing, along with the growth of blood brain barrier is perfect, the lead that storage is stayed in the brain is difficult to get rid of, and may cause child's brain permanent lesion and mental retardation.1991 American National Center for Disease Control (CDC) (CDC) on the basis of a large amount of clinical and epidemiologic datas, the diagnostic criteria of determining children ' s lead poisoning is BPb 〉=100ug/L, and no matter whether corresponding symptom and other blood and chemical change are arranged, this standard is accepted by the various countries scholar, certainly children ' s lead poisoning described here is not represented the poisoning on the clinical meaning, but lead load has been in the danger level that impairs children's health in the expression body.
Preventing and treating saturnine basic principle is environment intervention, health education and clinical treatment three combinations, the environment intervention is basic, health education is a basic means, and to being that the lead poisoning of BPb 〉=200ug/L is just considered clinical treatment more than the moderate, this is because the clinical treatment medicine mainly contains calcium disodium chelate (CaNa at present
2EDTA), sodium dimercaptosuccinate (DMSA) etc., though driving lead, medicine can reduce lead load in the body, Plumbum removing is effective, but the side effect that has renal damage and essential trace element to run off, and drive nervous lesion that plumbous medicine causes lead and reverse and have little significance, so the medicine Plumbum removing removes the severe lead poisoning, clinically generally do not adopt.
Chinese invention patent publication number CN1600159A once disclosed " Semen Cassiae functional food and preparation method thereof ", adopted Semen Cassiae, Fructus Crataegi, and Flos Chrysanthemi, preparations such as Radix Glycyrrhizae are used for the prevention and the auxiliary treatment food of hypertension, cardiovascular and cerebrovascular disease; Chinese invention patent publication number CN1454528A once disclosed " a kind of Semen Cassiae drink producing method ", adopt Semen Cassiae single raw material, by curing, decocting in water, technologies such as filtration have obtained reducing serum cholesterol, activate ocular tissue's milk surum deoxygenase, prevent the beverage of myopia.
Semen Cassiae is the dry mature seed of leguminous plant Semen Cassiae Cassia obtusifolia L. or little Semen Cassiae Cassia tora L., and Chinese medicine thinks that it has clearing away heat to improve acuity of vision, functions of loosening bowel relieving constipation; Clinical foreign body sensation and pain in the eye commonly used, it is dizzy to have a headache, constipation; Modern pharmacological research proves that it has blood pressure lowering, blood fat reducing, rushes down following, bacteriostasis; Do not see bibliographical information but whether Semen Cassiae has the human body of promotion lead-eliminating effect.
Summary of the invention
The object of the invention provides Semen Cassiae or its extract promotes the medicine of lead-eliminating effect or the application in the health product in preparation.
Adopt Semen Cassiae or its extract as raw material, single with or with other drug regimens with lead-eliminating effect routinely formulation method can be prepared into and be fit to oral any dosage form, as tablet, capsule, electuary, oral liquid etc., and health product.Wherein other medicines with lead-eliminating effect comprise one or more in Fructus Lycii, Fructus Alpiniae Oxyphyllae, Concha Ostreae, taurine, Semen Coicis, Rhizoma Smilacis Glabrae, the Herba Lysimachiae etc.
The present invention is that screening obtains having the Semen Cassiae that clearly promotes lead-eliminating effect from medicine and food raw materials, can reach and promote the plumbous purpose of human body being damaged, improves symptom of Plumbum removing, alleviation or prevention, and have no side effect, be suitable for the higher crowd of blood lead and take for a long time, especially at the child.
The specific embodiment
The invention will be further elaborated below in conjunction with embodiment.
Embodiment 1
50 of healthy Kunming mouses, a cleaning level animal, male female half and half, body weight 18～22 grams; Animal is divided into 5 groups, and promptly the blank group is dyed plumbous model group, 3 dosage groups of high, medium and low Semen Cassiae decocting liquid, and 10 every group, lead acetate is dissolved in the distilled water by the 40mg/kg lumbar injection, set up mice and dye plumbous animal model.
Semen Cassiae decocting liquid adopts conventional decocting method preparation, and simmer down to respective concentration, each medication group gastric infusion, decocting liquid various dose group comprises high dose group (6g/kg), middle dosage group (3g/kg), low dose group (1.5g/kg) is gastric infusion respectively, and all the other each groups gavage the equivalent normal saline, and the experiment successive administration is totally 6 weeks.Administration is got mice right femoral vein blood 40ul after finishing, putting into the plastic centrifuge tube with cover that fills 0.36ml1% nitric acid shakes up: get a side 50% femur, digest after weighing, add rare nitric acid and be settled to 5ml, with corresponding liver and the cerebral tissue got of method, with atomic spectrophotometer carry out blood and bone, liver, the brain lead content is measured; Above-mentioned data statistics is checked with T.
Table 1 Semen Cassiae decocting liquid to mice blood lead, bone lead, liver and brain lead (mg/kg) content influence (x ± s, n=10)
aCompare P＜0.05 with model group
bCompare P＜0.01 with the blank group
Semen Cassiae decocting liquid is obvious to the blood lead content influence, and low middle high dose group and model group relatively have significant difference P＜0.05; Semen Cassiae decocting liquid is obvious to the influence of bone lead content, and low middle high dose group and model group relatively have significant difference P＜0.05; Semen Cassiae decocting liquid is obvious to the influence of liver lead content, and low middle high dose group and model group relatively have significant difference P＜0.05-0.01; Semen Cassiae decocting liquid is obvious to the influence of brain lead content, and high dose group and model group relatively have significant difference P＜0.05.
Embodiment 2
50 of healthy Kunming mouses, a cleaning level animal, male female half and half, body weight 18～22 grams; Animal is divided into 5 groups, and promptly the blank group is dyed plumbous model group, 3 dosage groups of high, medium and low Semen Cassiae decocting liquid, and 10 every group, lead acetate is dissolved in the distilled water by the 40mg/kg lumbar injection, set up mice and dye plumbous animal model.
Take by weighing Semen Cassiae and Fructus Lycii by same weight proportion, adopt conventional decocting method to prepare Semen Cassiae Fructus Lycii decocting liquid, and simmer down to respective concentration, each medication group gastric infusion, the various dose group comprises high dose group (12g/kg), middle dosage group (6g/kg), and low dose group (3g/kg) is gastric infusion respectively, all the other each groups gavage the equivalent normal saline, and the experiment successive administration is totally 6 weeks.Administration is got mice right femoral vein blood 40ul after finishing, and puts into the plastic centrifuge tube with cover that fills 0.36ml1% nitric acid and shakes up; Get a side 50% femur, digest after weighing, add rare nitric acid and be settled to 5ml, with corresponding liver and the cerebral tissue got of method, with atomic spectrophotometer carry out blood and bone, liver, the brain lead content is measured; Above-mentioned data statistics is checked with T.
Table 1 Semen Cassiae Fructus Lycii decocting liquid to mice blood lead, bone lead, liver and brain lead (mg/kg) content influence (x ± s, n=10)
aCompare P＜0.05 with model group
bCompare P＜0.01 with the blank group
Semen Cassiae Fructus Lycii decocting liquid is obvious to the blood lead content influence, and low middle high dose group and model group relatively have significant difference P＜0.05; Semen Cassiae Fructus Lycii decocting liquid is obvious to the influence of bone lead content, and low middle high dose group and model group relatively have significant difference P＜0.05; Semen Cassiae Fructus Lycii decocting liquid is obvious to the influence of liver lead content, and low middle high dose group and model group relatively have significant difference P＜0.05-0.01; Semen Cassiae Fructus Lycii decocting liquid is obvious to the influence of brain lead content, and middle high dose group and model group relatively have significant difference P＜0.05.
Embodiment 3
1 clinical data selects 64 examples that 6～12 years old child of plumbous contact history arranged, and Pb-B all more than 100 μ g/L, has been got rid of the child of systemic diseases such as suffering from cardiovascular, liver, kidney and hemopoietic system and chronic diarrhea arranged and dyspeptic child; Do not take and tried thing or add other article identical with the observation effect, it is heavy to influence the youngster that effect is judged or data is incomplete.Counter point between own control and group is adopted in this test, with satisfactory 64 routine children, be divided into Semen Cassiae decocting liquid group and placebo group randomly according to blood lead, lead in urine level, observation group's 34 examples, male 15 examples, women 19 examples, 6～12 years old age, on average (9.32 ± 2.78) year, lead content in urine average out to (7.51 ± 5.36) (μ g/L), blood lead content average out to (133.17 ± 18.63) (μ g/L); Matched group 30 examples, male 16 examples, women 14 examples, 6～12 years old age, average (9.51 ± 2.38) year, lead content in urine average out to (6.61 ± 4.56) (μ g/L), blood lead content average out to (137.17 ± 21.16) (μ g/L).Two groups of basic conditions compare, and difference does not have significance (P＞0.05), has comparability, carries out clinical observation by blind method.
2 instructions of taking Semen Cassiae decocting liquid child every days early, respectively take 1 evening, and the matched group child respectively takes comfort oral liquid and Semen Cassiae decocting liquid outward appearance every day sooner or later, taste is basic identical; All accepted to observe 30 days for two groups.
The every observation index of 3 observation index is measured respectively by test requirements document.
3.1 perquisition is tried the child and the head of a family thereof before the safety viewing test, understands the physical condition of being tried the child, all is tried the child carry out conventional physical examination and necessary lab testing.Routine blood test: red blood cell count(RBC), numeration of leukocyte, hemoglobin counting; Routine urinalysis: proportion, ph value, leukocyte.
Before 3.2 the effect observation is observed and observe back blood lead and lead in urine output
4 statistical procedures data represent with mean ± standard deviation, self paired data pairing T check, T check between data set in groups.
5 results
Before and after observing self relatively, blood lead content obviously descends, the lead in urine output, obviously increase.
5.1 safety indexes
Routine blood test the results are shown in Table 1 before and after taking, and the every index of blood routine examination has no significant change before and after being observed by the visible two groups of observation children of table 1, and all in normal range.Every index of routine urianlysis does not have significant change.
Blood routine examination situation before and after table 1 is observed
5.2 effect index
Treatment of table 2 liang group and treatment back blood lead and lead content in urine be (μ g/L, x ± s) relatively
Annotate:
△Self compare with observation is preceding P＜0.05,
△ △P＜0.01, and compare between observation group's group,
▲Compare with observation group P＜0.01,
▲ ▲Compare before and after P＜0.01 observation group self.
By table 2 as seen, observe children taking after 30 days blood lead content obviously descend, observation group self relatively and observe between back observation group and matched group group and compare, blood lead and lead content in urine difference have significance (P＜0.01).
Claims (4)
1. the Semen Cassiae list is used or is promoted lead-eliminating effect medicines to promote the medicine of lead-eliminating effect or the application in the health product in preparation with other.
2. the Semen Cassiae extract list is used or is promoted lead-eliminating effect medicines to promote the medicine of lead-eliminating effect or the application in the health product in preparation with other.
3. application according to claim 1 and 2, medicine wherein or health product are peroral dosage form.
4. application according to claim 1 and 2, wherein other promote the lead-eliminating effect medicine to comprise one or more in Fructus Lycii, Fructus Alpiniae Oxyphyllae, Concha Ostreae, taurine, Semen Coicis, Rhizoma Smilacis Glabrae and the Herba Lysimachiae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101003474A CN100394930C (en) | 2005-10-19 | 2005-10-19 | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101003474A CN100394930C (en) | 2005-10-19 | 2005-10-19 | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1768778A CN1768778A (en) | 2006-05-10 |
| CN100394930C true CN100394930C (en) | 2008-06-18 |
Family
ID=36750483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101003474A Expired - Fee Related CN100394930C (en) | 2005-10-19 | 2005-10-19 | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100394930C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105192599A (en) * | 2015-08-14 | 2015-12-30 | 慧谷生命科技湖北有限公司 | Lead removing particles and preparation method thereof |
| CN106605914A (en) * | 2016-08-11 | 2017-05-03 | 西安源森生物科技有限公司 | Composition capable of lubricating the intestines, relaxing the bowels, expelling toxin and expelling lead, as well as preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1309133A (en) * | 2000-02-16 | 2001-08-22 | 潘晓东 | Neotoralactone, its derivatives and their application in reducing fat and lossing weight |
| CN1390594A (en) * | 2002-07-30 | 2003-01-15 | 成都国嘉药物研究所 | Mixture for improving blood circulation |
-
2005
- 2005-10-19 CN CNB2005101003474A patent/CN100394930C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1309133A (en) * | 2000-02-16 | 2001-08-22 | 潘晓东 | Neotoralactone, its derivatives and their application in reducing fat and lossing weight |
| CN1390594A (en) * | 2002-07-30 | 2003-01-15 | 成都国嘉药物研究所 | Mixture for improving blood circulation |
Non-Patent Citations (2)
| Title |
|---|
| 中草药排铅领域之研究概况. 张俊清.中国职业医学，第29卷第4期. 2002 |
| 中草药排铅领域之研究概况. 张俊清.中国职业医学，第29卷第4期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1768778A (en) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN104606612A (en) | Alcohol-expelling kidney-tonifying tablet candy and preparation method thereof | |
| CN102028900A (en) | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof | |
| CN103705854A (en) | Semen cassiae, fructus lycii and glossy privet fruit oral solution with functions of tonifying liver and reducing fat | |
| CN110074243A (en) | It is a kind of with relieving the effect of alcohol and protect the pressed candy of liver function | |
| CN1895547B (en) | Medicine for treating diabetes and its preparation | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN104524416A (en) | Pharmaceutical composition, and use and preparation method of pharmaceutical composition as well as medicine, food and/or health food prepared from pharmaceutical composition | |
| CN103623296A (en) | Preparation method of extract of traditional Chinese medicine with functions of regulating qi, relieving pain, invigorating stomach and promoting digestion | |
| CN109528904A (en) | A kind of kidney-tonifying health-care, boosting qi and nourishing yin, pharmaceutical composition of high-content ginsenoside and preparation method thereof | |
| CN102258628B (en) | Chinese medicinal composition with lead removal promoting effect | |
| CN100394930C (en) | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product | |
| CN101427720A (en) | High-concentration infusion tea for treating diabetes and method of producing the same | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN100350954C (en) | Chinese medicine preparation for promoting lead-removal and its preparation process | |
| CN101596265B (en) | Traditional Chinese medicine compound preparation for enhancing body fatigue resistance | |
| CN100525801C (en) | Application of plantain herb in preparing medicine and health article with lead removal promoting effect | |
| CN100473409C (en) | Medicine for treating glomerular hematuria | |
| CN101548993B (en) | Application of Japanese climbing fern spore in preparing lead excretion medicines or health products | |
| CN101810679A (en) | Polyunsaturated fatty acid soft capsule and preparation method thereof | |
| CN102579816B (en) | Brain-invigorating tablets and preparation method thereof | |
| CN100488546C (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN102716260B (en) | Medicine for fast improving sperm quality and sexual function | |
| CN101940765B (en) | Medicament for treating chronic cerebral circulation insufficiency and preparation method | |
| CN102552677B (en) | Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080618 Termination date: 20101019 |